The development and production of new-generation nuclear medicine radiopharmaceuticals have emerged in the global pharmaceutical industry. Nuclear medicine radiopharmaceuticals, which have the three functions of precise targeting, diagnosis and treatment, allow the cancer treatment process to take into account the quality of life and have a higher cure rate. Market research firm MEDraysintell estimates that between 2020 and 2030, global radiotherapy drugs will grow at an astonishing annual compound growth rate of 33%, while radiodiagnostic drugs will also grow at an annual compound growth rate of 6%, and the combined annual output value of radiodiagnostic drugs will be nearly US$30 billion.

There are many new nuclear medicine radiopharmaceuticals available worldwide for the diagnosis of prostate cancer, neuroendocrine tumors, and Alzheimer's disease. However, due to insufficient overall production capacity, supply in Taiwan currently exceeds demand, and only a few medical centers can use them. In order to benefit more patients in Taiwan, nuclear medicine radiopharmaceutical expert Dr. Huang Yayao and Winstar Technology CEO Dr. Ye Zhaoyuan co-founded Primer Biotech. In the past two years, they have attracted top talents in precision medicine to join the company, forming a professional team that is rare in Taiwan and spans the fields of radiopharmaceuticals and PIC/S GMP pharmaceuticals. The core team includes radiopharmaceutical and nuclear medicine experts from National Taiwan University Hospital, Taipei Veterans Affairs Hospital, and Linkou Chang Gung Memorial Hospital, as well as senior pharmaceutical professionals from major domestic biotech companies. In addition to building a stable and high-quality nuclear medicine radiopharmaceutical supply chain, Primer Biotech is also actively establishing strategic partnerships with Envision Medical and domestic and foreign biotech companies, looking forward to making great contributions to global medicine with its outstanding new-generation smart medical technology.

Award-winning achievements

2021 The company was founded and won the 18th National Innovation Award in the Clinical Innovation Category.

2023 Won the 7th Taipei City Outstanding Enterprise Selection Investment Model Award